Influence of Precursor Solution Composition on the Electrical Properties of Solution-Processed Indium Tin Oxide Thin Films by Jingwei Zhang (288128)

“…The results reveal that incorporating nitrate anion-based precursors and Sn (II)-based precursors in the solutions leads to the ITO film with a low resistivity of 3.5 × 10^–3 Ω cm. …”

Influence of Precursor Solution Composition on the Electrical Properties of Solution-Processed Indium Tin Oxide Thin Films by Jingwei Zhang (288128)

“…The results reveal that incorporating nitrate anion-based precursors and Sn (II)-based precursors in the solutions leads to the ITO film with a low resistivity of 3.5 × 10^–3 Ω cm. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Enhanced Anticorrosion, Antifouling, and Tribological Properties of PANI Composite Coating Reinforced by PVA, 2‑Aminophenol, and Acrylic to Fabricate Sustainable Passive Film on 30... by Mobina Moradi (18812975)

“…However, due to poor physical stability and tribological properties, PANI/PVA is copolymerized by various amounts (0.25–1 M) of 2-aminophenol (2-AP) and covered by a thin layer of acrylic (AC). According to the results, not only is the corrosion resistance of PANI/PVA/AP@AC about 100 times higher than PANI/PVA in 3.5 wt % NaCl (EIS), but its wear rate has also decreased by ∼60% (pin-on-disk). …”

List of NTM isolates used in this study. by Paul Breen (5211830)

“…<i>abscessus</i> isocitrate lyase (ICL) decreased enzymatic activity. Lastly, the addition of cell-permeable 4-octyl itaconate (4-OI) to THP-1 cells enhanced NTM clearance, demonstrating a potential role for IA/itaconate in host defense against NTM infections.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Raw data used for generating figures. by Paul Breen (5211830)

“…<i>abscessus</i> isocitrate lyase (ICL) decreased enzymatic activity. Lastly, the addition of cell-permeable 4-octyl itaconate (4-OI) to THP-1 cells enhanced NTM clearance, demonstrating a potential role for IA/itaconate in host defense against NTM infections.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Image_1_Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System.TIF by Pascal Urwyler (8133468)

“…Immediate defervescence occurred, and inflammatory markers and oxygen supplementation decreased or stabilized in 4 patients (e.g., median C-reactive protein 203 (range 31–235) mg/L before vs. 32 (12–72) mg/L on day 5). …”

Identification of Potent DNA Gyrase Inhibitors Active against Mycobacterium tuberculosis by Bongkochawan Pakamwong (12315428)

“…Thirty compounds were identified and selected as hits for in vitro biological assays, of which two compounds, <b>G24</b> and <b>G26</b>, inhibited the growth of M. tuberculosis H37Rv with a minimal inhibitory concentration of 12.5 μg/mL. …”

Impact of SARS-CoV-2 pandemic on ophthalmological emergency visits: 1 year of experience by Lucas Zago Ribeiro (12684959)

Genomic analysis of CrBV. by Xian Li (201841)

Patient-reported outcomes and experiences following bariatric surgery. by Trisha O’Moore-Sullivan (10276421)

S1 File - by Ama tul Zahra (17941364)

“…Investigations show that the tunable domain of ±<i>γ</i>(%) strains decreases from (-10%≤ <i>γ</i> ≤+19%) to (-5%≤ <i>γ</i> ≤+10%) for (8,0) SWCNTs and the buckling process shifts to lower ±<i>γ</i>(%) for (12,0) SWCNTs with increasing <i>T</i>(K). …”

Subgroup analyses of the aortic lesion area. by SiJin Li (12488187)

Proportions of patients with potential PASC symptoms*. by Noa Kopplin (14203462)

Initial stages of bud development. by Dharini Chittaragi (12506593)

Distribution of time to cardiac surgery following preoperative cardiac arrest (pCA). by Amulya Vadlakonda (15449215)

Later stages of bud development. by Dharini Chittaragi (12506593)

Functional diversity of VSMC subpopulations. by Ya-Kun Gao (12280161)